New drug combo aims to control relapsed blood cancer
NCT ID NCT06967610
Summary
This study is testing whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after prior treatment. It will enroll about 40 adults to see if this time-limited treatment can achieve deep remission and is safe. The main goal is to measure how well the treatment clears cancer cells from the bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.